211 related articles for article (PubMed ID: 35134754)
1. CLINICAL PHASES OF CHRONIC HEPATITIS B AMONG GEORGIAN PATIENTS.
Zakalashvili M; Butsashvili M; Zarkua J; Abzianidze T; Kamkamidze G; Metreveli D
Georgian Med News; 2022 Jan; (322):26-29. PubMed ID: 35134754
[TBL] [Abstract][Full Text] [Related]
2. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract][Full Text] [Related]
3. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
[TBL] [Abstract][Full Text] [Related]
4. The prognosis and management of inactive HBV carriers.
Invernizzi F; Viganò M; Grossi G; Lampertico P
Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
[TBL] [Abstract][Full Text] [Related]
6. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
[TBL] [Abstract][Full Text] [Related]
7. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
[TBL] [Abstract][Full Text] [Related]
8. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
9. Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens.
Liu C; Wu W; Shang S; Huang E; Xun Z; Lin J; Chen T; Yang B; Chen J; Ou Q
J Med Virol; 2019 Feb; 91(2):249-257. PubMed ID: 30011350
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction?
Fujiko M; Chalid MT; Turyadi ; Ie SI; Maghfira ; Syafri ; Wahyuni R; Roni M; Patellongi I; Massi MN; Muljono DH
Int J Infect Dis; 2015 Dec; 41():83-9. PubMed ID: 26571304
[TBL] [Abstract][Full Text] [Related]
11. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.
Choi GH; Kim GA; Choi J; Han S; Lim YS
Aliment Pharmacol Ther; 2019 Jul; 50(2):215-226. PubMed ID: 31135074
[TBL] [Abstract][Full Text] [Related]
12. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.
Gil-García AI; Madejón A; Francisco-Recuero I; López-López A; Villafranca E; Romero M; García A; Olveira A; Mena R; Larrubia JR; García-Samaniego J
World J Gastroenterol; 2019 Oct; 25(38):5883-5896. PubMed ID: 31636479
[TBL] [Abstract][Full Text] [Related]
14. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
[TBL] [Abstract][Full Text] [Related]
16. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
Chu CM
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
[TBL] [Abstract][Full Text] [Related]
17. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone.
Yao K; Liu J; Wang J; Yan X; Xia J; Yang Y; Wu W; Liu Y; Chen Y; Zhang Z; Li J; Huang R; Wu C
J Viral Hepat; 2021 Jul; 28(7):1025-1033. PubMed ID: 33797145
[TBL] [Abstract][Full Text] [Related]
18. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
[TBL] [Abstract][Full Text] [Related]
19. Importance of CHB's grey zone: analysis of patients with HBeAg negative chronic hepatitis B virus infection.
Lenartova PD; Hockickova I; Janicko M; Jarcuska P; Drazilova S; Lami F; Schreter I; Kristian P
Bratisl Lek Listy; 2024; 125(1):59-63. PubMed ID: 38041848
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial.
Ive P; MacLeod W; Mkumla N; Orrell C; Jentsch U; Wallis CL; Stevens W; Wood R; Sanne I; Bhattacharya D
PLoS One; 2013; 8(12):e74900. PubMed ID: 24324573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
